BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Clinical trial NCT06854003 · RECRUITING
Trial details
- NCT number
- NCT06854003
- Sponsor
- Christine Ryan
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-22
- Primary completion
- 2029-11-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.